Thrombotic Microangiopathy: Current Knowledge and Outcomes With Plasma Exchange

Seminars in Dialysis

Volumn 25, Issue 2, 2012, Pages 214-219

  Clark, William F ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HOSPITALIZATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PLASMAPHERESIS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADULT; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PLASMAPHERESIS; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

EID: 84858705735     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.01035.x     Document Type: Article

References (53)

1. Moschcowitz E: An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. An undescribed disease. Arch Intern Med 36(1):89-93, 1925
2. Gasser C, Gauthier E, Steck A, Siebenmann RE, Oechslin R: Hamolytisch-uramische syndromes bilaterale nierenrindennekrosen bei akuten erworbenchen hamolytischen anamien. Schweiz Med Wschr 85:905-909, 1955
3. Amorosi EL, Ultmann JE: Thrombotic thrombocytopenic purpura: report of 16 cases and review of literature. Medicine (Baltimore) 45:139-159, 1966
4. Rubenstein MA, Kagan BM, MacGillviray MH, Merliss R, Sacks H: Unusual remission in a case of thrombotic thrombocytopenia purpura syndrome following fresh blood exchange transfusions. Ann Intern Med 51:1409-1419, 1959
5. Bukowski RM, Hewlett JS, Harris JW, Hoffman GC, Battle JD, Silverblatt E, Yang I-Y: Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. Semin Hematol 13:219-232, 1976
6. Garthwaite T, Laurie A, Aster RH, Kaminskas E, Pisciotta AV: Remission in thrombotic thrombocytopenic purpura apparently induced by exchange transfusion [abstract]. Clin Res 24:570A, 1976
7. Bukowski RM, King JW, Hewlett JS: Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 50(3):413-417, 1977
8. Byrnes JJ, Khurana M: Treatment of thrombotic thrombocytopenic purpura with plasma. NEJM 297(25):1386-1389, 1977
9. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, the Canadian Apheresis Study Group: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenia purpura. NEJM 325(6):393-397, 1991
10. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D: Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307(23):1432-1435, 1982
11. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B: Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. NEJM 339(22):1578-1584, 1998
12. Tsai H-M, Lian EC-Y: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. NEJM 339(22):1585-1594, 1998
13. Lammle B, Kremer Hovinga JA, George JN: Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica 93(2):172-177, 2008
14. Vesely SK, George JN, Lammle B, Studt J-D, Alberio L, El-Harake MA, Raskob GE: ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102(1):60-68, 2003
15. Mannucci PM, Peyvandi F: TTP and ADAMTS13: when is testing appropriate? Am Soc Hematol Educ Program 2007(1):121-126, 2007
16. George JN, Kremer Hovinga JA, Terrell DR, Vesely SK, Lammle B: The Oklahoma thrombotic thrombocytopenia purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection. Eur J Haematol compilation 80:277-286, 2000
17. Bell WR, Braine HG, Ness PM, Kickler TS: Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. NEJM 325(6):398-403, 1991.
18. Rock G, Kelton JG, Shumak KH, Buskard NA, Sutton DMC, Benny WB, Members of the Canadian Apheresis Group: Laboratory abnormalities in thrombotic thrombocytopenic purpura. Brit J Haematol 103:1031-1036, 1998
19. Forzley BR, Sontrop JM, Macnab JJ, Chen S, Clark WF: Treating TTP/HUS with plasma exchange: a single centre's 25-year experience. Brit J Haematol 143:100-106, 2008.
20. George JN, Vesely SK, Terrell DR: The Oklahoma thrombotic thrombocytopenic purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 41(1):60-67, 2004
21. Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM: Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 53(2):259-272, 2009
22. Rock G, Clark W, Sutton D, Canadian Apheresis Group, Canadian Association of Apheresis Nurses: The Canadian Apheresis Registry. Transfus Apher Sci 29(2):167-177, 2003
23. Fakhouri F, Fremeaux-Bacchi V: Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? Nat Clin Pract Nephrol 3(12):679-687, 2007
24. Desch K, Motto D: Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome? J Am Soc Nephrol 18:2457-2460, 2007
25. Harker LA, Slichter SJ: Platelet and fibrinogen consumption in man. N Engl J Med 287(20):999-1005, 1972
26. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H: The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151(5):775-782, 1985
27. Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Pietrement C, Champion G, Ulinski T, Deschenes G: Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5:1218-1228, 2010
28. Baron JM, Baron BW: Thrombotic thrombocytopenic purpura and its look-alikes. Clin Adv Hematol Oncol 3(11):868-874, 2005
29. Bitzan M: Treatment options for HUS secondary to Escheirchia coli 0157:H7. Kidney Int 75(Suppl. 112):S62-S66, 2009
30. Fujimara Y, Matsumoto M, Yagi H: Thrombotic microangiopathy. In: Tanaka K, Davie EW (eds). Recent Advances in Thrombosis and Hemostasis, 1st edn, Vol. XXI. Tokyo: Springer, 2008:625-639
31. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN: The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 3:1432-1436, 2005
32. Martin DL, MacDonald KL, White KE, Soler JT, Osterholm MT: The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med 323:1161-1167, 1990
33. Brunskill SJ, Tusold A, Benjamin S, Stanworth SJ, Murphy MF: A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med 17:17-35, 2007
34. Clark WF, Forzley BR, Sontrop JM, Kadri A, Moist LM, Suri RS, Salvadori MS, Garg AX: TTP/HUS: observational studies generate hypotheses that lead to randomized controlled trials. Kidney Int 75(Suppl. 112):S50-S51, 2009
35. Dragon-Durey M-A, Loirat C, Cloarec S, Macher M-A, Blouin J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V: Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:555-563, 2005
36. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanogglu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship THJ: Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 100:12966-12971, 2003
37. De Horge EG, Pickering MC: Atypical hemolytic uremic syndrome: telling the difference between H and Y. Kidney Int 78:721-723, 2010
38. Rosales A, Reidl M, Zimmerhackl LB: Atypical HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol 6:504-506, 2010
39. Tsai H-M: Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time? Kidney Int 77:267-269, 2010
40. Garg AX, Salvadori M, Moist LM, Suri RS, Clark WF: Renal prognosis of toxigenic Escherichia coli infection. Kidney Int 75(Suppl. 112):S38-S41, 2009
41. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF: Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290(10):1360-1370, 2003
42. Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ: Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apher 18:51-54, 2003
43. Dubois L, Gray DK: Splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura? Can J Surg 53(5):349-355, 2010
44. Allan DS, Kovacs MJ, Clark WF: Frequent relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 85(8):844-850, 2001
45. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ: Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to AdAMTS-13. Brit J Haematol 136:451-461, 2006
46. De la Rubia J, Moscardo F, Gomez MJ, Guardia R, Rodriguez P, Sebrango A, Zamora C, Deben G, Goterris R, Lopez R, Rena F, Pujol M, Vidaller A, del Rio-Garma J, Sanz MA, on behalf of the Grupo Espanol de Aferesis (GEA): Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci 43:299-303, 2010
47. Foley SR, Webert K, Arnold DM, Rock GA, Clark WF, Barth D, Sutton DA, Members of the Canadian Apheresis Group (CAG): A Canadian phase 2 study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int 75(Suppl. 112):S55-S58, 2009
48. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK: Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the transfusion medicine/hemostasis clinical trials network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 21:49-56, 2006
49. Viswanathan S, Rovin BH, Shidham GB, Raman SV, Weinberg M, Patricia A, George JN, Wu HM, Cataland SR: Long-term sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura. Brit J Haematol 149(4):623-625, 2010
50. Kennedy AS, Lewis QF, Scott JG, Kremer Hovinga JA, Lammle B, Terrell DR, Vesely LK, George JN: Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion 49(6):1092-1101, 2009
51. Leis QF, Lanneau MS, Mathias SD, Terrell DR, Vesely SK, George JH: Long-term deficits in health-related, quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion 49(1):118-124, 2009
52. Hawkins BM, Abu-Fadel M, Vesely SK, George JN: Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion 48(2):382-392, 2008
53. Clark WF, Sontrop JM, Macnab JJ, Salvadori M, Moist L, Suri R, Garg AX: Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli 0157:H7: a prospective cohort study. BMJ 341:c6020, 2010